This inventor holds 1 USPTO granted patent. Top assignee: Duke University. Active years: 2002.
Company Filing History:
Years Active: 2002
Title: Innovations in Cardiac Gene Therapy by Howard A. Royman
Introduction
Howard A. Royman is a notable inventor based in Chapel Hill, NC (US). He has made significant contributions to the field of gene therapy, particularly in the treatment of chronic heart failure and other cardiac diseases. His innovative work focuses on enhancing myocardial function through advanced genetic techniques.
Latest Patents
Royman holds a patent titled "Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function." This invention addresses the challenges associated with reduced numbers or functioning of myocardial beta-adrenergic receptors (β-AR). The patent outlines a method for augmenting β-AR receptor function in transgenic animals by delivering and expressing a beta-2-adrenergic receptor gene or a gene encoding a beta-adrenergic receptor kinase inhibitor. This approach results in improved left ventricular function in vivo. The invention includes recombinant plasmid vectors, alternative beta-adrenergic receptor gene delivery strategies, and transgenic mice carrying relevant transgenes.
Career Highlights
Royman is affiliated with Duke University, where he continues to advance research in cardiac gene therapy. His work has the potential to transform treatment options for patients suffering from heart-related ailments.
Collaborations
Throughout his career, Royman has collaborated with esteemed colleagues, including Robert J. Lefkowitz and Carmelo A. Milano. These partnerships have further enriched his research and contributed to the advancement of cardiac therapies.
Conclusion
Howard A. Royman's innovative contributions to gene therapy represent a significant advancement in the treatment of cardiac diseases. His work continues to inspire future research and development in this critical area of medicine.